血浆MERTK是诊断和预后乙型肝炎病毒相关慢加急性肝衰竭的有前景生物标志物
本研究通过转录组学分析发现MERTK mRNA在HBV-ACLF患者中高表达,并预测28天和90天不良预后(AUROC分别为0.814和0.731)。外部验证285例血浆样本证实血浆MERTK对HBV-ACLF具有高诊断准确性(AUROC=0.859),对28天和90天死亡率有潜在预后价值(AUROC分别为0.673和0.644)。
要点
- MERTK mRNA在HBV-ACLF患者中高表达,预测28天和90天预后AUROC为0.814和0.731。
- 285例血浆外部验证显示MERTK诊断HBV-ACLF的AUROC为0.859。
- 血浆MERTK高于临界值的患者死亡风险更高。
核心结论
- MERTK有潜力作为HBV-ACLF早期诊断和预后的候选生物标志物。
研究设计与样本
- 研究通过转录组学分析评估MERTK在疾病进展中的表达和功能,并用酶联免疫吸附试验、受试者工作特征曲线下面积(AUROC)分析和肝组织免疫组化(IHC)验证MERTK对HBV-ACLF患者的诊断和预后意义,外部验证纳入285例血浆样本。
主要发现
- MERTK mRNA在HBV-ACLF患者中的表达高于肝硬化(LC)、慢性乙型肝炎(CHB)和正常对照(NC)患者。
- MERTK mRNA升高预测HBV-ACLF 28天和90天不良预后,AUROC分别为0.814和0.731。
- 功能分析显示MERTK与Toll样受体和炎症信号及若干关键生物学过程显著相关。
- 285例血浆样本外部验证证实血浆MERTK对HBV-ACLF具有高诊断准确性(AUROC=0.859),对28天和90天死亡率有潜在预后价值(AUROC分别为0.673和0.644)。
- 风险分层分析表明血浆MERTK水平高于临界值的患者死亡风险更高;IHC染色显示MERTK表达从NC、CHB、LC到HBV-ACLF逐渐增加。
关键数值与推荐
- 血浆MERTK诊断HBV-ACLF的AUROC=0.859(外部验证285例血浆样本)。
- 血浆MERTK预测28天死亡率AUROC=0.673,预测90天死亡率AUROC=0.644。
- MERTK mRNA预测28天预后AUROC=0.814,预测90天预后AUROC=0.731。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) has a high short-term mortality. This study aimed to determine the diagnostic and prognostic role of MER tyrosine kinase (MERTK) in patients with HBV-ACLF. METHODS: Transcriptomics analysis evaluated MERTK expression and function during disease progression. The diagnostic and prognostic significance of MERTK for patients with HBV-ACLF were verified by enzyme-linked immunosorbent assay, area under the receiver operating characteristic curve (AUROC) analysis, and immunohistochemistry (IHC) of liver tissues. RESULTS: MERTK mRNA was highly expressed in patients with HBV-ACLF compared to those with liver cirrhosis (LC), chronic hepatitis B (CHB), and normal controls (NC). Elevated MERTK mRNA predicted poor prognosis for HBV-ACLF at 28 and 90 days (AUROC = 0.814 and 0.731, respectively). Functional analysis showed MERTK was significantly associated with toll-like receptor and inflammatory signaling and several key biological processes. External validation with 285 plasma subjects confirmed the high diagnostic accuracy of plasma MERTK for HBV-ACLF (AUROC = 0.859) and potential prognostic value for 28- and 90-day mortality rates (AUROC = 0.673 and 0.644, respectively). Risk stratification analysis indicated higher mortality risk for patients with plasma MERTK level above the cutoff value. Moreover, IHC staining showed increasing MERTK expression from NC, CHB, and LC to HBV-ACLF. CONCLUSIONS: MERTK shows promise as a candidate biomarker for early diagnosis and prognosis of HBV-ACLF.
引用
- Lu Y, Xin J, Liang X, et al. Plasma MERTK Is a Promising Biomarker for the Diagnosis and Prognosis of Hepatitis B Virus-Related Acute-on-Chronic Liver Failure. J Infect Dis. 2024. PMID: 38373244. doi:10.1093/infdis/jiae079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。